Half of us ‘won’t get vaccine by end of 2021’
Vaccinating Britain will cost £12bn, the NHS will need 46,000 new staff – and still HALF of us ‘won’t get jab by end of 2021’, report reveals
- National Audit Office said the plans assumed that just 25million will receive jabs
- The NAO report found that vaccinating the whole population will cost £12billion
- It found taxpayer could be liable for legal costs if proves to be anything wrong
Vaccinating Britain will come at a cost of £12billion with the NHS needing 46,000 new staff – but half of us still won’t have received the jab by the end of 2021, a report has revealed.
The National Audit Office, which monitors government spending, said the plans assumed that just 25million will receive jabs if enough become available.
This would suffice for the priority groups – the over-50s, frontline health workers, those in care homes and people with underlying health conditions.
But it would leave younger adults waiting until 2022.
Its report also warned that the taxpayer could be liable to pay legal costs – on top of the £11.7bn cost of developing, buying and manufacturing the vaccine – should anything go wrong.
The figures come as coronavirus cases continue to climb. Daily cases hit 18,540 yesterday, up 50 per cent on last Tuesday, although deaths were down.
Rising cases in Sussex could see the county follow London and parts of Essex and Hertfordshire into Tier 3, as plans for Christmas hang in the balance.
As Matt Hancock revealed more than 1,000 cases of a new Covid strain had been identified, mainly in the South, experts have warned the latest variant does not appear to be more deadly, and the risk that it will be impervious to existing jabs is regarded as low.
The National Audit Office, which monitors government spending, said the plans assumed that just 25million will receive jabs if enough become available. Pictured: Patients in Harrow sit in an observation room after receiving their first dose of the Covid vaccine
Last night, NHS England insisted that the 25million figure was not a ceiling and that more Britons would receive jabs if they were available.
The NAO report found that vaccinating the whole population will cost £12billion – and that ministers agreed upfront payments of almost £1billion in total for five of the seven vaccine contracts it signed.
The watchdog found the taxpayer could be liable for legal costs if there proves to be anything wrong with any of the vaccines – as pharmaceutical firms demanded immunity from liability before signing contracts.
And it revealed that the Government may have to pay millions for vaccines even if they turn out not to work, because the contracts state the money cannot be returned.
The report said that once mass vaccination swings into action, GP capacity will not be enough – and 46,000 staff may need to be hired.
Many Britons will have to travel to sports stadiums, conference centres and airports for their jab. Pictured: Patients at The Hive in London
It said the Government was planning for a 75 per cent take-up rate of the jab.
Many Britons will have to travel to sports stadiums, conference centres and airports for their jab.
Sites such as polling stations could be used in areas with a high proportion of at-risk people and ‘roving vaccination sites’ could take the jab into care homes.
Gareth Davies, head of the NAO, said: ‘Government has worked quickly and effectively to secure access to potential vaccines, using the available information to make big decisions in an inherently uncertain environment.
‘With one vaccine now approved for use and its roll-out started, significant challenges remain. Efficient delivery to the UK population presents complex logistical challenges and requires excellent communication with the public.’
Matt Hancock has revealed there are up to 1,000 cases of a new Covid strain, but it is not thought to be impervious to existing vaccines
The number of coronavirus cases in England dropped by a quarter during the second national lockdown, a Government-backed study has revealed. Pictured: A graph showing a drop in the percentage of positive tests per 10,000 people when the second lockdown began in November
The report found that the Government had arranged deals for potential Covid-19 vaccines quickly.
But it said there may not be enough capacity to deliver them all without taking on tens of thousands of extra staff.
The document said: ‘Current understanding of the majority of vaccines is that each person will require two doses approximately four weeks apart for it to be effective. That equates to up to 50million vaccinations for Covid-19 alone.’
Meg Hillier, chair of the Commons Public Accounts Committee, told the The Times that Government was right to back a ‘number of horses,’ when searching for a vaccine, but said account accountability arrangements were ‘highly unusual’.
The NAO report has been published as talks are set to continue between the UK Government and the leaders of Scotland, Wales and Northern Ireland on whether to keep Christmas ‘bubbles’ allowing three households to mix from December 23.
The report said that once mass vaccination swings into action, GP capacity will not be enough – and 45,000 staff may need to be hired. Pictured: Patients at The Hive in London
Scottish First Minister Nicola Sturgeon told the Scottish Parliament she did not have a ‘fixed view’, but they would be looking at whether the duration or number of households that can mix should be reduced.
In a veiled threat she also said her administration will take whatever action it thinks is ‘appropriate’ even if there is no UK-wide agreement.
Mr Drakeford said the nations face a ‘grim choice’ with just eight days to go until the relaxed rules are due to come into effect, and many families already having made plans.
Nearly a quarter of the world may not have access to a vaccine until 2022, experts have warned.
They said high-income countries including the EU have reserved 51 per cent of doses, but make up only 13.7 per cent of the world population.
Writing in the British Medical Journal, experts from Johns Hopkins Bloomberg School of Public Health in the US said 13 developers have struck deals for 7.5billion doses in total, but only six have sold to low and middle-income nations, including Oxford/AstraZeneca and Novavax.
